NEW YORK (GenomeWeb) – The Cas9 nuclease from Staphylococcus aureus can be used to edit genomes as efficiently as Cas9 from Streptococcus pyogenes but at a smaller size, enabling CRISPR methods for in vivo applications that could eventually include therapeutic use, researchers reported today in a study published in Nature.